TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9202586

Group type: EXPERIMENTAL
Intervention: MRI with criterion 1 (lymph node diameter > 1.0 cm)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: MRI with criterion 2 (lymph node diameter > 0.5 cm with asymmetry)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Normal small asymmetric lymph nodes
Number of subjects: 216
Study: 1487885

Group type: EXPERIMENTAL
Intervention: Nitrogranulong 5.2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrogranulong 10.4 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Trinitrolong 2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrong 6.5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3954919

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 80
Study: 31919911

Group type: EXPERIMENTAL
Intervention: Dietary energy level (increased)
Number of subjects: 60
Study: 31236810

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 8 weeks, 3 times per week on a cycle ergometer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-exercise control (CON) group
Number of subjects: 30
Study: 28414741

Group type: EXPERIMENTAL
Intervention: Unfamiliar relaxing music
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unfamiliar arousing music
Number of subjects: 12
Study: 25623589

Group type: EXPERIMENTAL
Intervention: Antibiotic (oral sultamicillin) for five days
Number of subjects: 980

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 980
Study: 23931538

Group type: EXPERIMENTAL
Intervention: Modelling group (received modelling examples during training)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no modelling examples during training)
Number of subjects: 48
Study: 21292059

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 16
Study: 19074931

Group type: EXPERIMENTAL
Intervention: Dietary counselling and food fortification
Number of subjects: 59

Group type: COMPARATOR
Intervention: Dietary advice leaflet (Control)
Number of subjects: 59
Study: 16621446

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 15641866

Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine
Number of subjects: 70

Group type: COMPARATOR
Intervention: No antidepressant medication (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine (for treatment after diagnosis)
Number of subjects: 70
Study: 11157324

Group type: EXPERIMENTAL
Intervention: Tyrosine intake (graded intake)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tyrosine intake (safe intake)
Number of subjects: 6
Study: 9573545

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (30 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control infusion (30 g branched chain amino acids)
Number of subjects: 8
Study: 7836512

Group type: EXPERIMENTAL
Intervention: Ultrasonography monitoring
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ultrasonography and serum determinations
Number of subjects: 114
Study: 3400679

Group type: EXPERIMENTAL
Intervention: Cefoperazone 2 g intravenously every 12 hours and mezlocillin 4 g intravenously every six hours
Number of subjects: 78

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg intravenously over 30 to 60 minutes every six hours
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cefoperazone and mezlocillin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 78
Study: 29499675

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioural therapy (iCBT) for 8 weeks duration with regular post-session feedback by Psychological Wellbeing Practitioners
Number of subjects: 0

Group type: COMPARATOR
Intervention: waitlist control group
Number of subjects: 0
Study: 27508467

Group type: EXPERIMENTAL
Intervention: Transparent polyurethane film
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 25
Study: 25697860

Group type: EXPERIMENTAL
Intervention: CET plus D-cycloserine (50 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: CET plus placebo
Number of subjects: 76
Study: 23035053

Group type: EXPERIMENTAL
Intervention: Mental practice (MP) for 20 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (didactic teaching session for 20 min)
Number of subjects: 40
Study: 21604926

Group type: EXPERIMENTAL
Intervention: FANCI (First Steps Acute Neurobehavioural and Cognitive Intervention)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (watching videos)
Number of subjects: 72
Study: 19655818

Group type: EXPERIMENTAL
Intervention: Cardioselective beta-adrenoceptor antagonists (CSB); 212 patients (51% of 412 evaluable patients) were taking CSB.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (non-diabetic patients); not explicitly defined in the abstract.
Number of subjects: 222
Study: 16754416

Group type: EXPERIMENTAL
Intervention: 80 mg atomoxetine QD
Number of subjects: 218

Group type: COMPARATOR
Intervention: 40 mg atomoxetine BID
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Both QD and BID treatments
Number of subjects: 218
Study: 15317833

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 160 mg fenofibrate
Number of subjects: 12
Study: 11746067

Group type: EXPERIMENTAL
Intervention: COPE program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison group (audiotaped information)
Number of subjects: 42
Study: 9243686

Group type: EXPERIMENTAL
Intervention: HMEF (Pall BB25)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group without HMEF
Number of subjects: 40
Study: 8485533

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3222359

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg and 400 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High-to-moderate caffeine users
Number of subjects: 95

Group type: COMPARATOR
Intervention: 0 mg caffeine (control)
Number of subjects: 95
Study: 29589138

Group type: EXPERIMENTAL
Intervention: Mutated genes (PIK3CA, BRAF, KIT, PDGFRA, AKT1)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Wild-type tumors
Number of subjects: 135
Study: 28516793

Group type: EXPERIMENTAL
Intervention: Red wine consumption
Number of subjects: 157

Group type: COMPARATOR
Intervention: White wine consumption
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 157
Study: 26286133

Group type: EXPERIMENTAL
Intervention: 50 mL 4.2% sodium bicarbonate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 mL 4.2% sodium bicarbonate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 mL 2.1% sodium bicarbonate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study: 23447103

Group type: EXPERIMENTAL
Intervention: Peaceful Mind cognitive-behavioral therapy for anxiety in persons with dementia; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on intervention not available.
Number of subjects: 0
Study: 16898281

Group type: EXPERIMENTAL
Intervention: Self-confidence
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Worry and somatic symptom intensity
Number of subjects: 246

Group type: COMPARATOR
Intervention: High levels of self-confidence and low symptom intensity
Number of subjects: 246
Study: 12525233

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 87)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching control group (n = 86)
Number of subjects: 173
Study: 11601037

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 ng/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 6 ng/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane in oxygen without any other drugs (Control Group)
Number of subjects: 60
Study: 7776391

Group type: EXPERIMENTAL
Intervention: syrup with a 10-ml measuring cup
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: syrup with a 5-ml measuring spoon
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: tablets
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: single-dose sachets of antibiotic powder
Number of subjects: 400
Study: 2098143

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g intravenous infusion one hour before operation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g intravenous infusion one hour before operation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (without antibiotics)
Number of subjects: 60
Study: 6253099

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone: 4500 rads in 5-6 weeks to primary tumor and regional lymph nodes, and 3500 rads in 2 1/2 weeks to brain as prophylaxis.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) + chemotherapy (CT) with cyclophosphamide (500 mg/m2), Adriamycin (50 mg/m2), and DTIC (250 mg/m2) every 3 weeks for two cycles before RT and seven cycles post-RT.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RT + CT
Number of subjects: 70

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 70
Study: 30429927

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg IV ketamine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 34
Study: 26390231

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 0
Study: 25809682

Group type: EXPERIMENTAL
Intervention: Green leafy vegetable (cassia)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Serum PTH
Number of subjects: 19
Study: 23864538

Group type: EXPERIMENTAL
Intervention: 50 mg purified (-)-epicatechin perfused into an isolated jejunal segment
Number of subjects: 8
Study: 20299396

Group type: EXPERIMENTAL
Intervention: Sunbed use
Number of subjects: 9310

Group type: EXPERIMENTAL
Intervention: Sunbed use in the north
Number of subjects: 9310

Group type: EXPERIMENTAL
Intervention: Sunbed use in the Six Cities Study
Number of subjects: 9310

Group type: EXPERIMENTAL
Intervention: Mean age of first use
Number of subjects: 9310

Group type: EXPERIMENTAL
Intervention: Weekly sunbed use
Number of subjects: 9310

Group type: EXPERIMENTAL
Intervention: Home sunbed use
Number of subjects: 9310

Group type: EXPERIMENTAL
Intervention: Unsupervised sunbed use
Number of subjects: 9310
Study: 19127801

Group type: EXPERIMENTAL
Intervention: Cefper injection (1.5 g cefoperazone and sulbactam)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sulperazon injection (1.5 g cefoperazone and sulbactam)
Number of subjects: 24
Study: 15889524

Group type: EXPERIMENTAL
Intervention: Shenmai Injection plus routine treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine treatment only
Number of subjects: 48
Study: 12652091

Group type: EXPERIMENTAL
Intervention: 3-h workshop on problem drinking and alcohol dependence
Number of subjects: 76

Group type: COMPARATOR
Intervention: 3-h workshop on depression
Number of subjects: 76
Study: 10498560

Group type: EXPERIMENTAL
Intervention: Azithromycin (1.0-g dose)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Penicillin G benzathine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 96
Study: 8556221

Group type: EXPERIMENTAL
Intervention: Diarex Lactab (test preparation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Imodium capsules (reference preparation)
Number of subjects: 24
Study: 1682783

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6109585

Group type: EXPERIMENTAL
Intervention: Bevantolol 75 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bevantolol 150 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31082727

Group type: EXPERIMENTAL
Intervention: Intralesional rituximab
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intralesional triamcinolone
Number of subjects: 21
Study: 28933798

Group type: EXPERIMENTAL
Intervention: Warfarin 10 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tecarfarin 30 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (Healthy Volunteers)
Number of subjects: 23
Study: 24989721

Group type: EXPERIMENTAL
Intervention: Daily oral antioxidants in the form of multivitamins and minerals (amino acid chelated)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (no antioxidants)
Number of subjects: 218
Study: 23772021

Group type: EXPERIMENTAL
Intervention: Educational intervention based on social cognitive theory (7 sessions of 60 minutes)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 82
Study: 21852196

Group type: EXPERIMENTAL
Intervention: Lunch is in the Bag intervention
Number of subjects: 6
Study: 19302638

Group type: EXPERIMENTAL
Intervention: Combined Spinal Epidural (CSE)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Low-Dose Infusion (LDI)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: High-Dose Epidural (Control)
Number of subjects: 1052
Study: 18162669

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IN)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fixed angle blade plating (BP)
Number of subjects: 58
Study: 15513323

Group type: EXPERIMENTAL
Intervention: CEE + MPA (n = 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 28
Study: 11216925

Group type: EXPERIMENTAL
Intervention: Protease inhibitor-resistant isolates
Number of subjects: 14

Group type: COMPARATOR
Intervention: Protease inhibitor-sensitive isolates
Number of subjects: 14

Group type: COMPARATOR
Intervention: Protease inhibitor (PI)
Number of subjects: 14
Study: 9850370

Group type: EXPERIMENTAL
Intervention: 5 cmH2O PEEP
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 10 cmH2O PEEP
Number of subjects: 67

Group type: COMPARATOR
Intervention: Zero PEEP
Number of subjects: 67
Study: 7861712

Group type: EXPERIMENTAL
Intervention: Intermittent calcitriol therapy (oral or intraperitoneal doses) for 12 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intermittent calcitriol therapy
Number of subjects: 14
Study: 2518862

Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil
Number of subjects: 128

Group type: COMPARATOR
Intervention: 150 mg ranitidine
Number of subjects: 128
Study: 181692

Group type: EXPERIMENTAL
Intervention: Caffeine (1,000 mg daily)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bromocriptine (40 mg daily)
Number of subjects: 6
Study: 31714621

Group type: EXPERIMENTAL
Intervention: Resveratrol plus risperidone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 62
Study: 31297965

Group type: EXPERIMENTAL
Intervention: bexagliflozin (20 mg)
Number of subjects: 288

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 288
Study: 28550977

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) and Simvastatin (40mg/day) combination therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Simvastatin (40mg/day)
Number of subjects: 57
Study: 24517252

Group type: EXPERIMENTAL
Intervention: Danoprevir/r 200/100 mg plus P/R for 24 weeks (Arm A)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Danoprevir/r 100/100 mg plus P/R for 24 weeks (Arm B)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Danoprevir/r 50/100 mg plus P/R for 24 weeks (Arm C)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Danoprevir/r 100/100 mg plus P/R for 12 or 24 weeks (Arm D)
Number of subjects: 473

Group type: COMPARATOR
Intervention: P/R alone for 48 weeks (Arm E)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Danoprevir/r plus P/R in G1a-infected patients
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Danoprevir/r plus P/R in G1b-infected patients
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Danoprevir/r plus P/R in G4-infected patients
Number of subjects: 473
Study: 22382875

Group type: EXPERIMENTAL
Intervention: LED group (treadmill training with phototherapy, n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise group (treadmill training, n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sedentary group (n=10)
Number of subjects: 30
Study: 20889211

Group type: EXPERIMENTAL
Intervention: Low-dose peginterferon-α2a 90 μg/week
Number of subjects: 129

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 129
Study: 19091452

Group type: EXPERIMENTAL
Intervention: Parallel-sided glass-fiber posts with hybrid composite core material
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Parallel-sided glass-fiber posts with dual-cure composite core material
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Tapered glass-fiber posts with hybrid composite core material
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Tapered glass-fiber posts with dual-cure composite core material
Number of subjects: 192
Study: 17182419

Group type: EXPERIMENTAL
Intervention: In-Person Aftercare
Number of subjects: 177

Group type: COMPARATOR
Intervention: Telephone Aftercare
Number of subjects: 177

Group type: COMPARATOR
Intervention: No-Active Aftercare
Number of subjects: 177
Study: 12616178

Group type: EXPERIMENTAL
Intervention: Behavioral graded activity and problem-solving therapy (GAPS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Behavioral graded activity and group education (GAGE)
Number of subjects: 84
Study: 11771959

Group type: EXPERIMENTAL
Intervention: hsp90 protein levels in SLE patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 levels in SLE patients
Number of subjects: 0
Study: 8694309

Group type: EXPERIMENTAL
Intervention: 10 mL/kg crystalloid volume
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 20 mL/kg crystalloid volume
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 30 mL/kg crystalloid volume
Number of subjects: 55
Study: 1563055

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl given before delivery
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl given after delivery
Number of subjects: 64
Study: 3926848

Group type: EXPERIMENTAL
Intervention: Combined treatment with intraaortic balloon pumping and intravenous nitroglycerin for 4 to 5 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined treatment with intraaortic balloon pumping and intravenous nitroglycerin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine management
Number of subjects: 20
Study: 29120861

Group type: EXPERIMENTAL
Intervention: Active 20Hz rTMS at 110% of Motor Threshold
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 29
Study: 28066111

Group type: EXPERIMENTAL
Intervention: Low-cost brand (LCB) amlodipine 5 mg once daily for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Innovator brand (IB) amlodipine 5 mg once daily for 6 weeks
Number of subjects: 28
Study: 24251855

Group type: EXPERIMENTAL
Intervention: 3-day Family Constellation Seminars (FCSs)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 208
Study: 23076666

Group type: EXPERIMENTAL
Intervention: Psychosocial counselling
Number of subjects: 42

Group type: COMPARATOR
Intervention: Information brochure about dementia
Number of subjects: 42
Study: 21510459

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone at a dose of 4 microg/Kg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18951261

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 mcg BID
Number of subjects: 647

Group type: COMPARATOR
Intervention: Salmeterol (SAL) 50 mcg BID
Number of subjects: 647

Group type: COMPARATOR
Intervention: Montelukast (MON) 10 mg once daily
Number of subjects: 647
Study: 16160735

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 38
Study: 12020486

Group type: EXPERIMENTAL
Intervention: VANQWISH stress test criteria (exercise and pharmacologic nuclear stress testing)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: FRISC‐II criteria for catheterization
Number of subjects: 385
Study: 10207534

Group type: EXPERIMENTAL
Intervention: Tunnel restorations using glass cermet cement, Ketac Silver.
Number of subjects: 374
Study: 7884423

Group type: EXPERIMENTAL
Intervention: Vincristine and dactinomycin (VA)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Vincristine, dactinomycin, and cyclophosphamide (VA + C)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Intensive regimens of IRS‐III
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Pulsed VAC or VAC-VADRC in IRS‐II
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Complex therapies evaluated in IRS‐III
Number of subjects: 1062
Study: 2198311

Group type: EXPERIMENTAL
Intervention: Local hyperthermia at 42-43 degrees C before radiotherapy (33 patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Radiotherapy alone (32 patients)
Number of subjects: 65
Study: 353681

Group type: EXPERIMENTAL
Intervention: Experimental diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 46
Study: 7181476

Group type: EXPERIMENTAL
Intervention: Ceforanide (two-dose regimen)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cephalothin (six-dose regimen)
Number of subjects: 150
Study: 30665464

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30183338

Group type: EXPERIMENTAL
Intervention: Continuous moderate-intensity exercise (CMIE: 30 min, 50% peak power output)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE: 5 × 4 min, 75% peak power output, work matched to CMIE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-volume sprint interval exercise (SIE: 4 × 30 s)
Number of subjects: 8

Group type: COMPARATOR
Intervention: All protocols (CMIE, HIIE, SIE)
Number of subjects: 8